11 results
DRS
VIR
Vir Biotechnology Inc
27 Jun 19
Draft registration statement
12:00am
are not known, but there is additional evidence supporting the need for immune stimulation to achieve a functional cure.
HBV Life Cycle and Undetectable … HBsAg as a Clinical Endpoint
The viral life cycle of HBV is shown in the figure below. After infecting a cell, the virus forms cccDNA. This form of HBV
S-1
VIR
Vir Biotechnology Inc
3 Sep 19
IPO registration
4:40pm
are not known, but there is additional evidence supporting the need for immune stimulation to achieve a functional cure.
HBV Life Cycle and Undetectable … HBsAg as a Clinical Endpoint
The viral life cycle of HBV is shown in the figure below. After infecting a cell, the virus forms cccDNA. This form
424B4
VIR
Vir Biotechnology Inc
11 Oct 19
Prospectus supplement with pricing info
5:31pm
evidence supporting the need for immune stimulation to achieve a functional cure.
HBV Life Cycle and Undetectable HBsAg as a Clinical Endpoint
The viral … life cycle of HBV is shown in the figure below. After infecting a cell, the virus forms cccDNA. This form of HBV DNA is located in the nucleus
DRS/A
msfk6 i7yf
7 Aug 19
Draft registration statement (amended)
12:00am
10-K
5ipgh1s
26 Mar 20
Annual report
4:08pm
S-1/A
ymcv3nfpji
30 Sep 19
IPO registration (amended)
6:12am
S-1
EX-10.16
09pn07hcqj4184
3 Sep 19
IPO registration
4:40pm
DRS/A
EX-10.16
gt2j9alf
7 Aug 19
Draft registration statement (amended)
12:00am
- Prev
- 1
- Next